Skip to main content
GALT
NASDAQ Life Sciences

Officer Jamil Khurram files intent to sell additional shares after recent significant sales

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$4.12
Mkt Cap
$268.234M
52W Low
$0.94
52W High
$7.13
52W Position info
338% above low
Off High info
42% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

GALT has more than doubled off its 52-week low of $0.94.

Summary

An officer of Galectin Therapeutics has filed a Form 144 to sell additional shares, following approximately $799,099 in sales over the last three months.


Key Events · Ownership and Investor Activity · GALT

  • Officer's Intent to Sell

    Officer Jamil Khurram filed a Form 144 indicating an intent to sell 8,125 shares of common stock, valued at approximately $33,313.

  • Recent Significant Sales

    The filing also disclosed that the same officer has sold 140,559 shares for gross proceeds of approximately $799,099 over the past three months.

  • Cumulative Insider Selling

    The combined recent and proposed sales by this officer total over $832,000, representing a notable reduction in insider holdings.


Analysis · GALT · Life Sciences

This Form 144 filing indicates that Officer Jamil Khurram intends to sell 8,125 shares of common stock. More significantly, the filing also discloses that Mr. Khurram has already sold 140,559 shares for gross proceeds of approximately $799,099 over the past three months. This pattern of consistent selling by an officer, totaling over $832,000 in recent and proposed sales, could be interpreted negatively by investors as it suggests a reduction in insider ownership and conviction.

How filings like this one have moved

In the 30 days to Sep 17, 2026, 29.7% of the 1739 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.34%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, GALT was trading at $4.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $268.2M. The 52-week trading range was $0.94 to $7.13. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

GALT - Latest Insights

GALT
Aug 14, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.45
Real-time Price: $3.88 info
Change: +$0.430 (+12%) info
Market Cap: $371.127M info
GALT
Aug 14, 2026, 7:55 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.49
Real-time Price: $3.88 info
Change: +$0.390 (+11%) info
Market Cap: $371.127M info
GALT
Aug 04, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $3.21
Real-time Price: $3.88 info
Change: +$0.670 (+21%) info
Market Cap: $371.127M info
GALT
Aug 04, 2026, 7:50 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.06
Real-time Price: $3.88 info
Change: +$0.820 (+27%) info
Market Cap: $371.127M info
GALT
Jun 23, 2026, 7:53 AM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $2.77
Real-time Price: $3.88 info
Change: +$1.11 (+40%) info
Market Cap: $371.127M info